Lamisil

Terbinafine, the active ingredient in Lamisil, is an allylamine antifungal presented as an oral dosage form for oral use. It treats dermatophyte infections such as athlete’s foot, body ringworm, and fungal nail infections in adult patients and are commonly prescribed for superficial mycoses of the skin and nails.

GNH USA supplies Lamisil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU regulatory standards and is available for bulk distribution across Europe, Asia, Africa and the Americas.

Lamisil (terbinafine) is used to treat fungal infections affecting the skin, hair and nails. - Tinea pedis (athlete’s foot): eradicates the dermatophyte causing foot skin infection. - Tinea corporis (body ringworm): clears the fungal infection of the body skin. - Onychomycosis (fungal nail infection): promotes regrowth of healthy nail by eliminating the causative fungus. - Tinea cruris (jock itch): treats fungal infection of the groin area. - Tinea capitis (scalp ringworm): eliminates the fungus causing scalp infection.

Oral terbinafine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort or dyspepsia. - Headache: mild to moderate intensity. - Taste disturbance: altered taste perception or loss of taste.

Serious or Rare Side Effects: - Hepatotoxicity: clinically significant liver injury or hepatitis. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Peripheral neuropathy: numbness, tingling or burning sensations in the limbs.

Before prescribing oral terbinafine, clinicians should consider several precautionary measures to ensure patient safety. - Liver function assessment: obtain baseline hepatic enzymes and monitor periodically. - Drug interactions review: evaluate concomitant medications that affect CYP2D6. - Pregnancy and lactation counseling: avoid use unless benefits outweigh potential risks. - Renal impairment adjustment: assess kidney function in patients with severe renal disease. - Age considerations: use caution in elderly patients due to increased risk of adverse effects. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture.

Terbinafine can interact with other medicines, altering its concentration or the effect of co‑administered drugs.

Major Interactions (Avoid): - Itraconazole: combined use may increase risk of hepatotoxicity. - Cimetidine: may raise terbinafine plasma levels, enhancing toxicity.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., fluoxetine, paroxetine): terbinafine can inhibit metabolism, requiring dose adjustment. - Warfarin: may potentiate anticoagulant effect, monitor INR. - Antacids containing aluminum or magnesium: may reduce terbinafine absorption, separate dosing.